Recently, a CTLA-4 antibody and BRAF inhibitors showed survival benefits in advance melanoma treatment. The documentation of immune infiltrates in melanomas early during BRAF inhibitor therapy provides a scientific rationale for combination therapy with both treatments with possible synergistic benefits. This commentary reviews immune responses induced by BRAF inhibitors.
Marcel A. Deken, Jules Gadiot, Ekaterina S. Jordanova, Ruben Lacroix, Melissa van Gool, Paula Kroon, Cristina Pineda, Marnix H. Geukes Foppen, Richard A Scolyer, Ji‐Ying Song, Inge Verbrugge, Christoph Höeller, Reinhard Dummer, John B.A.G. Haanen, Georgina V. Long, Christian U. Blank
Claire Martin, Carleen Cullinane, Laura Kirby, Shatha AbuHammad, Emily J. Lelliott, Kelly Waldeck, Richard J. Young, Natalie Brajanovski, Donald P. Cameron, Rachael Walker, Elaine Sanij, Gretchen Poortinga, Ross D. Hannan, Richard B. Pearson, Rodney J. Hicks, Grant A. McArthur, Karen E. Sheppard
Su Yin Lim, Jenny Lee, Tuba N. Gide, Alexander M. Menzies, Alexander Guminski, Matteo S. Carlino, Edmond J. Breen, Jean Yang, Shila Ghazanfar, Richard F. Kefford, Richard A Scolyer, Georgina V. Long, Helen Rizos
Su Yin Lim, Jenny Lee, Tuba N. Gide, Alexander M. Menzies, Alexander Guminski, Matteo S. Carlino, Edmond J. Breen, Jean Yang, Shila Ghazanfar, Richard F. Kefford, Richard A Scolyer, Georgina V. Long, Helen Rizos
Discussion(0)
No comments yet. Be the first to comment.